Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s stock price traded down 6.2% during mid-day trading on Tuesday . The company traded as low as $0.51 and last traded at $0.54, 1,736,375 shares changed hands during trading. An increase of 34% from the average session volume of 1,298,153 shares. The stock had previously closed at $0.57.
A number of research analysts recently issued reports on the company. Dawson James upgraded Adamis Pharmaceuticals to a “buy” rating and set a $1.00 price target on the stock in a report on Monday, June 15th. Zacks Investment Research downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, June 11th. Finally, Maxim Group reiterated a “buy” rating and set a $1.50 target price on shares of Adamis Pharmaceuticals in a report on Tuesday, June 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $1.09.
The business has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.56. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.04. The stock has a market cap of $42.74 million, a PE ratio of -1.12 and a beta of 1.98.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its earnings results on Monday, May 18th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.11). Adamis Pharmaceuticals had a negative return on equity of 76.02% and a negative net margin of 140.34%. The firm had revenue of $4.66 million for the quarter, compared to analysts’ expectations of $6.87 million. On average, research analysts predict that Adamis Pharmaceuticals Corp will post -0.29 earnings per share for the current year.
An institutional investor recently bought a new position in Adamis Pharmaceuticals stock. Sabby Management LLC purchased a new position in Adamis Pharmaceuticals Corp (NASDAQ:ADMP) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 88,210 shares of the specialty pharmaceutical company’s stock, valued at approximately $32,000. Sabby Management LLC owned approximately 0.12% of Adamis Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 15.69% of the company’s stock.
Adamis Pharmaceuticals Company Profile (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Article: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.